FINAL PROGRAM - American Society of Gene & Cell Therapy

More documents

Recommendations

Info

13 th AnnUAL MEETing | Washington, DC USA May 19-22, 2010 65Program ScheduleFoundation Symposium 3407:00 pm - 10:00 pmRoom: Marriott Ballroom Salons 2 & 3Progress and Prospects for Gene Therapy for CGD and other Primary ImmunodeficienciesSpeakersMary C. Dinauer, MD, PhDGene Therapy for CGD - From Basic Discoveries to the Start of Clinical TrialsAlessandro Aiuti, MD, PhDConditioning Regimens for Haematopoietic Gene TherapyHarry L. Malech, MDUpdate on Gene Therapy Trials for CGDManuel Grez, PhDThe European Experience on GT for CGDAdrian J. Thrasher, MD, PhDUpdate on Clinical Trials for XC1-SCID, ADA and ALDFoundation Symposium 340 is supported by the following ASGCT partner:Friday, May 21 st
66American Society of Gene & Cell TherapyProgram ScheduleSaturday, May 22ASGCT Business Meeting8:00 am - 8:30 amRoom: Delaware SuiteA light continental breakfast will be served at 7:45 am.Scientific Symposium 4008:30 am - 10:30 amRoom: Maryland SuiteLate Stage Industry Clinical TrialsCo-ChairsDouglas J. Jolly, PhD & Thomas TillettSpeakersWilliam W. Li, MDGene Transfer of FGF1 for Critical Limb Ischemia: A Phase III Clinical TrialRobert Sims, MDProgress in the Development of Sipuleucel-T for the Treatment of Men with Metastatic, Castrate Resistant Prostate CancerSipuleucel-T is an autologous cellular immunotherapy designed to elicit an antitumor response against prostate cancer. Sipuleucel-T is manufactured by incubating antigenpresenting cell precursors with a fusion protein composed of prostatic acid phosphatase linked to GM-CSF. Sipuleucel-T is then reinfused into the patient and the process isrepeated every 2 weeks for a total of 3 infusions. It has been evaluated in 3 randomized placebo-controlled Phase 3 studies in men with metastatic castrate-resistant prostatecancer, which have demonstrated clear evidence of prolongation of survival. The presentation will include an update on the regulatory status of sipuleucel-T currentclinical trials, as well as planned future trials.Ryuichi Morishita, MD, PhDDevelopment of HGF Gene Therapy Drug (Collategen)As HGF is a most potent mitogen to stimulate angiogenesis, a multi-center randomized, placebo-controlled, double blind study for critical limb ischemia (CLI) using HGFplasmid DNA was conducted, based on phase I/IIa open label study at Osaka University. Improvement rate was 70.4 % in HGF and 30.8% in placebo in Fontaine III/Rutherford 4 patients (P=0.014). HGF gene therapy achieved a significantly higher improvement rate of ischemic ulcers compared with placebo (100% vs. 40%,P=0.018). No major safety problems were observed. Based on phase III data, NDA was submitted to Japan Regulatory Agency (MHWL) on 2008. In USA, phase IIIstudy using HGF gene therapy will be started in 2010, since phase III USA study obtained SPA from FDA.Sander van Deventer, MD, PhDGlybera for Lipoprotein Lipase DeficiencySaturday, May 22 ndEXHIBITOR PROSPECTUSfinal program
Page 1 and 2:
FINAL PROGRAMAmerican Society of Ge
Page 4:
13 th AnnUAL MEETing | Washington,
Page 7 and 8:
6American Society of Gene & Cell Th
Page 12 and 13:
Page 20 and 21: 13 th AnnUAL MEETing | Washington,
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 127 and 128:
126American Society of Gene & Cell
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
show all

FINAL PROGRAM - American Society of Gene & Cell Therapy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?